5% Vs 10% Nano-Hydroxyapatite Toothpaste Tablets: What Should Brands Specify Beyond The Percentage?

TAKEAWAYS

• Three figures make a percentage auditable: record the raw-material addition, the agreed HAp-content basis, and the target or verified mg per finished tablet. An OEM quote that gives only “5%” or “10%” is incomplete.

• 1–100 nm is terminology, not an automatic pass: ISO/TR 18401 uses that nanoscale range as a terminology context. Request the measurement method, distribution, and whether it describes primary particles, crystallites, or agglomerates before using “nano” in a material file.

• Ca/P ≈ 1.667 is a composition reference, not a commercial tolerance: it is the theoretical ratio for idealized hydroxyapatite. A buyer still needs lot-specific Ca and P results, the method, and phase-identity support.

• A five-analyte impurity panel needs individual evidence when risk and market assessment select it: report lead, arsenic, cadmium, mercury, and antimony separately with units, method, and LOQ/LOD where relevant—not as a generic “heavy metals pass” statement.

• Two control levels are necessary: an incoming-material COA supports the powder; finished-tablet checks support blend dispersion, per-tablet amount, breakup, mouthfeel, and packaging stability.

• One written control package protects the project: a capable toothpaste-tablet OEM should align the formula, material lot, test method, sample plan, and change-control route before mass production—not after a percentage appears on artwork.

5% and 10% Are Formulation Statements, Not Complete Specifications

Neither percentage is meaningful until its basis is written down. A buyer may be comparing raw powder added to a blend, a dry-basis figure, an assay-supported HAp content, or a calculated percentage of final tablet mass. Those are not automatically the same figure.

Use three linked values in every quotation and approval record:

1. Raw-material addition — the mass of the supplied powder or suspension dispensed into the batch.

2. Agreed HAp-content basis — the definition used to describe the material content, including whether moisture, carrier, coating, or another component is included.

3. Finished-tablet amount — the target and, where appropriate, verified amount on the agreed basis in one tablet.

A useful buyer request is: “Please show the numerator, denominator, % w/w basis, formula version, tablet net mass, and whether this is a target calculation or a release result.” This keeps a 10% offer based on as-supplied material from being compared casually with a 5% offer based on dry, assay-supported material.

For broader material qualification and sample gates, see Qiaoerna’s nHAp toothpaste tablet material and batch-control guide.

First Specify the Percentage Basis and the Amount per Tablet

The percentage should resolve into a per-tablet target before the formula is approved. A calculation is not a claim of measured delivery; it is the control point that lets the buyer reconcile dispensing, yield, tablet mass, and finished-product testing.

Do not relabel a weighed raw-material addition as chemically confirmed nHAp content unless the definition and method support that wording. If the project needs an individual-tablet result, agree the analytical approach or validated surrogate before pilot approval—not after production has started.

Problem #1 — A “Nano” Label Without a Defined Measurand Is Not a Specification

“Nano” must say what was measured and how. ISO/TR 18401 describes nanoscale principally as 1–100 nm, but that terminology does not establish a universal toothpaste-tablet acceptance limit.[1] It also does not make a powder “nano grade” merely because a trade name or one average value says so.

Ask the supplier to separate these measurements:

• Primary-particle dimensions — commonly observed by microscopy, with morphology and distribution.

• Crystallite size — a different material descriptor, often associated with diffraction analysis.

• Aggregate or agglomerate profile — what the particles are clustered into as supplied or in a prepared dispersion.

• Dry-powder or wet-dispersion distribution — a method-dependent result that needs sample-preparation conditions.

The 2025 SCCS opinion illustrates why the boundaries matter. Its conclusion applies to a specifically characterized nHAp material: rod-shaped particles, at least 87% by particle number with aspect ratios no greater than 3, the remaining 13% no greater than 9, a maximum length reported as 122 ± 43 nm, and no coating or surface modification.[3] It is not a generic “nano-HAp approval,” and it does not automatically cover a different morphology, coating, treatment, or supplier grade.

Request the instrument and method, dispersion procedure, relevant distribution statistics, representative data or images, lot linkage, and a plain declaration of whether the material is uncoated, coated, surface-modified, doped, or carrier-containing.

Problem #2 — Purity, Ca/P, and Surface Treatment Are Separate Evidence Streams

One “high purity” line cannot prove material identity, composition, and surface state at once. A useful material file answers different questions separately:

Idealized calcium hydroxyapatite is represented by Ca₁₀(PO₄)₆(OH)₂, giving a theoretical Ca/P molar ratio of about 1.667. NIST’s archived SRM 2910a reference-material certificate reports 1.667 ± 0.037 for that specific reference material, with stated measurement uncertainty.[2] Use these numbers as disciplined composition context—not as a commercial tolerance copied into every nHAp tablet specification.

The practical rule is simple: ask for Ca results, P results, the method, the calculation basis, and phase evidence together. A reagent ratio, marketing name, or calcium assay alone does not close the identity question.

Problem #3 — “Heavy Metals Pass” Is Not a Lot-Specific COA

A heavy-metal statement is usable only when the analytes, method, units, detection capability, and lot are visible. For mineral-containing oral-care projects, define the impurity panel through source/process risk and the destination-market review. At a minimum, buyers often discuss lead, arsenic, cadmium, mercury, and antimony as separate analytes.

Health Canada’s cosmetic guidance lists policy values of 10 ppm lead, 3 ppm arsenic, 3 ppm cadmium, 1 ppm mercury, and 5 ppm antimony in its Canadian context, while emphasizing product context and case-by-case assessment.[4] These figures are not universal global toothpaste-tablet specifications. They are a reason to ask the right question, not a license to copy a limit into any market.

A lot-specific COA or supporting laboratory report should show:

• material identity, legal supplier/manufacturer, lot, date, and document revision;

• result for each agreed analyte, units, test method, and LOQ/LOD where relevant;

• sample preparation or digestion basis where relevant;

• the applicable specification or risk-assessment basis; and

• quality approval plus a link to the delivered material lot.

COA triage: A generic TDS describes a grade; a lot-specific COA links numerical results to the delivered lot; a supporting analytical report should explain method and reporting capability when the COA cannot. Escalate “nano” or “high purity” without definition, one undefined particle-size number, missing surface-state disclosure, “heavy metals pass” without individual results/LOQs, or any document without a lot link.

“ND” is not self-explanatory. It only becomes meaningful when the analyte, method, unit, and reporting limit are stated. For a more detailed document-control discussion, see Qiaoerna’s guide to heavy-metal documentation.

Translate the Powder File into Blend and Tablet Controls

A qualified nHAp powder can still behave differently after blending and compression. Density differences, agglomeration, electrostatic behavior, order of addition, pre-blending, milling or sieving, lubricant distribution, transfer, hopper residence, and press settings can affect how material is distributed through a tablet batch.

FDA’s cosmetic GMP inspection guidance supports written manufacturing instructions, use of approved materials, sampling during or after processing where appropriate, testing of raw materials, in-process samples, and finished products against established specifications, and retention of control records.[5] It does not set a universal nHAp tablet limit. It supports the discipline of agreeing the control plan before production.

For a project-specific qualification, request an evidence chain from nHAp lot to final tablet:

1. approved material and formula version;

2. weighed-addition and batch reconciliation record;

3. defined mixing and transfer controls;

4. a sampling rationale for the blend and/or compression stage; and

5. individual-tablet assay or a scientifically justified surrogate when the project requires verification of the agreed tablet-level basis.

A bulk blend result is not automatically evidence that every tablet has the agreed amount. The sample plan, analytical basis, acceptance criteria, handling of out-of-specification results, and trend review all need written agreement for the formula and target market.

Release the Finished Tablet, Not Just the Ingredient

The finished tablet must be accepted as a product, not as a carrier for a raw-material COA. Its review should cover both the agreed nHAp basis and the characteristics that affect handling and use.

Do not assume smaller nominal primary particles always deliver a smoother experience. Mouthfeel is a finished-formula outcome. It depends on the material state, agglomeration, abrasives, sweeteners, flavor system, tablet breakup, and user conditions.

Use the separate toothpaste-tablet quality controls and stability testing before launch resources to extend this article’s nHAp-specific control package into an SKU-level release plan.

Ask an OEM to Quote Against a Written Control Package

The best RFQ makes the material, the tablet, and the commercial decision traceable. It should not ask only for “5% nHAp” or “10% nHAp.”

Before an OEM quote or sample request, provide this brief:

• target markets and intended label/claim direction;

• percentage denominator, % w/w basis, tablet net mass, and target mg/tablet basis;

• material identity/grade, nano-characterization expectations, and surface-treatment position;

• required COA/TDS/SDS, identity and impurity evidence, and change-control expectations;

• formula, flavor, sensory, tablet-shape, and packaging requirements;

• sample stage, pilot/production approval gates, and finished-tablet release evidence; and

• requested MOQ, sampling scope, documentation scope, and production milestone plan.

That detail allows an OEM to distinguish a standard formula from a custom specification. It also makes later supplier, material, or packaging changes visible. For the commercial choice, see custom specification versus a standard formula. For product-format options, visit Qiaoerna’s toothpaste tablets category.

FAQ: nHAp Toothpaste Tablet OEM, Samples, Documents, and MOQ

Is 10% nHAp automatically better than 5% in a toothpaste tablet?

No. Compare the percentage basis, target mg per tablet, material identity, nano-characterization, surface state, impurity evidence, tablet-level consistency, breakup behavior, mouthfeel, and stability plan. A higher nominal addition is not automatically better, safer, smoother, or more appropriate for the project.

What MOQ should a brand expect for 5% or 10% nHAp toothpaste tablets?

MOQ is a commercial question tied to the exact formula version, tablet weight and shape, flavor, packaging, artwork, documentation, and market route—not to the percentage alone. Ask the OEM for a written MOQ against the final SKU brief and state whether material qualification or special testing is required.

Can brands request a sample before placing an OEM order?

Yes. Treat the development sample as a decision point, not automatic proof of production equivalence. Request the sample formula version, nHAp lot, percentage basis, tablet mass, packaging assumption, material documents, and the plan for what will be repeated or verified on production lots.

Which documents should an nHAp toothpaste-tablet supplier provide?

Request a lot-specific nHAp COA, TDS, SDS, material identity and nano-characterization support, surface-treatment declaration, agreed impurity evidence, traceability and change-control information. For finished tablets, request batch and formula traceability, agreed physical and tablet-level checks, packaging/stability evidence, and market-specific documentation defined with qualified regulatory reviewers.

Can an OEM customize nHAp percentage, tablet weight, flavor, or packaging?

An OEM may be able to customize these variables, but each change should be made measurable. State the percentage basis, target mg/tablet, material profile, tablet mass, sensory brief, packaging requirements, markets, claims boundaries, and release evidence. A change can require a new qualification or stability plan.

What is the lead time for a customized nHAp tablet project?

Confirm lead time after the actual scope is known: material availability or qualification, sample iterations, packaging/artwork, document review, pilot scheduling, production capacity, and any required testing. Request written milestones for sampling, sourcing, approval, production, and release instead of relying on an assumed number of days or weeks.

Does a raw-material COA prove that every tablet contains the declared nHAp amount?

No. A raw-material COA supports the incoming material only to the documented extent. It does not prove blend dispersion, tablet mass consistency, tablet-to-tablet amount, breakup, mouthfeel, packaging stability, or batch equivalence. Request a traceable finished-product verification plan.

Build the Percentage into a Verifiable Product Plan

The defensible answer to 5% versus 10% is not a universal winner. It is a written, testable specification that connects the percentage basis to the actual nHAp material, supplied lot, formula process, per-tablet target, finished-tablet release, and controlled changes.

At Qiaoerna, an nHAp toothpaste-tablet OEM discussion can begin with that control package: material documents, formula route, sensory and packaging brief, sample stage, and market requirements. Contact admin@qiaoerna.com.cn or use the Qiaoerna contact page to discuss a private-label toothpaste-tablet project.

Author: Xiaoying, Head of R&D, Qiaoerna Biotechnology Co., Ltd.
Technical review: Qiaoerna Quality & Compliance Team — material-document, manufacturing-control, and claims-boundary review.

References

1. International Organization for Standardization (2017). ISO/TR 18401:2017 Nanotechnologies — Plain language explanation of selected terms from the ISO/IEC 80004 series.
   URL: https://www.iso.org/obp/ui/#iso:std:iso:tr:18401:ed-1:v1:en
   → Key finding: describes nanoscale principally as 1–100 nm for terminology context; it does not set a toothpaste-tablet release criterion.

2. National Institute of Standards and Technology (2008). Standard Reference Material 2910a: Calcium Hydroxyapatite, Certificate of Analysis (archived reference-material certificate). URL: https://tsapps.nist.gov/srmext/certificates/archives/2910a.pdf
   → Key finding: reports a certified Ca/P molar ratio of 1.667 ± 0.037 for this reference material; it is not a commercial nHAp specification.

3. Scientific Committee on Consumer Safety (2025). Scientific Opinion on Hydroxyapatite (nano) — Submission IV, SCCS/1677/25. European Commission; adopted 26 June 2025.
   URL: https://health.ec.europa.eu/publications/sccs-scientific-opinion-hydroxyapatite-nano-submission-iv_en
   → Key finding: the opinion is limited to its defined material characteristics and does not apply to needle-shaped, coated, or surface-modified materials.

4. Health Canada (2017). Guidance on Heavy Metal Impurities in Cosmetics.
   URL: https://www.canada.ca/en/health-canada/services/consumer-product-safety/reports-publications/industry-professionals/guidance-heavy-metal-impurities-cosmetics.html
   → Regulatory context: provides Canadian cosmetic impurity-policy values and explains that product context and case-by-case assessment matter.

5. U.S. Food and Drug Administration (2025). Good Manufacturing Practice (GMP) Guidelines/Inspection Checklist for Cosmetics.
   URL: https://www.fda.gov/cosmetics/cosmetics-guidance-documents/good-manufacturing-practice-gmp-guidelinesinspection-checklist-cosmetics
   → Quality-system context: covers controls for raw materials, in-process samples, finished-product specifications, records, and retained samples; it does not create a universal nHAp tablet specification.